Study of ICP-332 for prurigo nodularis
Part of Skin clinical trials.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had prurigo nodularis for at least 3 months, diagnosed by a skin doctor.
- You have at least 20 bumps on your body, on both sides (like both arms or legs) at your screening and first study visit.
- Your average itch severity is 7 or higher on a 0–10 scale at both screening and first visit.
- You have tried medium or strong prescription steroid creams and they didn't work well, or you can't use them for safety reasons.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called lebrikizumab can reduce severe itching and skin bumps caused by prurigo nodularis (a chronic skin condition). The drug works by calming an overactive immune response in the skin.
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This trial tests an investigational drug called MG-K10 for people with prurigo nodularis, a skin condition that causes intense itching and bumps. The goal is to see if it can help reduce itch and improve skin.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
Hear when a new Prurigo Nodularis (PN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.